EGFR and breast carcinoma: In addition, C225-ILs-DOX showed 29-fold greater cytotoxicity than the corresponding non-targeted liposomal DOX in EGFR-overexpressing MDA-MB-468 breast cancer cells.193 In the U87/EGFRvIII tumor model, which overexpresses both EGFR and EGFRvIII, C225-ILs-DOX achieved 6-fold greater cellular accumulation than non-targeted liposomes.